← Back to Search

Alkylating agents

Early Stage Cohort - Arm A for Endometrial Cancer (CAN-STAMP Trial)

Phase 2 & 3
Led By Amit Oza, MD
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Local TP53 results must be available for Central review.
Eastern Cooperative Group (ECOG) performance status ≤ 2 (Karnofsky ≥60%).
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group

CAN-STAMP Trial Summary

This trial is studying how well different treatment regimens work in treating patients with serous or p53 abnormal endometrial cancer.

Who is the study for?
This trial is for women with serous or p53 abnormal endometrial cancer who've had optimal surgery, have a performance status ≤2, and available tissue samples. They must understand the consent form, not have received prior treatment for this cancer, and agree to contraception. Exclusions include previous chemotherapy for endometrial cancer, certain mixed tumors, recent radiotherapy affecting bone marrow, uncontrolled illnesses that affect study compliance, known brain metastases unless stable post-treatment over 1 month, pregnancy, active HIV or Hepatitis B/C on therapy.Check my eligibility
What is being tested?
The trial tests if external beam radiation (EBRT) improves disease-free survival compared to vaginal brachytherapy after chemotherapy in early-stage patients. For advanced stages, it examines whether maintenance with Niraparib increases progression-free survival. It's an umbrella two-arm phase II trial where participants are randomly assigned to treatments.See study design
What are the potential side effects?
Potential side effects may include local reactions from radiation like skin irritation or discomfort during brachytherapy application; fatigue; digestive issues; blood disorders from Niraparib such as low platelet counts or anemia; and increased risk of infections due to immune system suppression.

CAN-STAMP Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
My TP53 test results are ready for review.
I can take care of myself but might not be able to do heavy physical work.
I have existing tissue samples, or I am willing to undergo a biopsy.
My cancer is in stage I or II.
My TP53 test results are ready for review.
I have existing tissue samples, or I am willing to undergo a biopsy.
I am considered a good candidate for surgery.
I can take care of myself but might not be able to do heavy physical work.
My endometrial cancer is either serous type or has a specific gene mutation.
My organ and bone marrow functions are normal as of the last 8 days.

CAN-STAMP Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Disease Free Survival Rate
Secondary outcome measures
Number Adverse Events Experienced
Overall Survival Rate

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

CAN-STAMP Trial Design

4Treatment groups
Experimental Treatment
Active Control
Group I: Early Stage Cohort - Arm B1Experimental Treatment2 Interventions
Vaginal high-dose rate brachytherapy 21 Gy in 3 fractions, prescribed to 5mm (i.e. 100% isodose at 5mm) from the cylinder/applicator surface and top along the upper third to half of the vagina (minimum 3cm, maximum 4cm).
Group II: Early Stage Cohort - Arm AExperimental Treatment1 Intervention
Pelvic EBRT at 45Gy in 25 fractions, in 1.8Gy fractions daily, 5 days per week
Group III: Advanced Stage Cohort Arm D1Experimental Treatment1 Intervention
Investigational agent (niraparib), orally, at a dose of 200 mg, or 300 mg, once daily, based on baseline platelet count and weight.
Group IV: Advanced Stage Cohort Arm CActive Control1 Intervention
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved
External Beam Radiation
Completed Phase 2

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,451 Previous Clinical Trials
482,879 Total Patients Enrolled
6 Trials studying Endometrial Cancer
969 Patients Enrolled for Endometrial Cancer
Amit Oza, MDPrincipal InvestigatorPrincess Margaret Cancer Centre
4 Previous Clinical Trials
619 Total Patients Enrolled
1 Trials studying Endometrial Cancer
44 Patients Enrolled for Endometrial Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are people still able to enroll in this trial?

"Yes, that is accurate. The most recent information on clinicaltrials.gov suggests that this study is still recruiting patients. This trial was posted on November 17th 2020 with the last edit being made on May 20th 2021. There is a goal to enroll 120 people total from 1 location."

Answered by AI

What is the standard protocol for Carboplatin?

"Carboplatin is not only useful in treating advanced endometrial cancer, but can also be taken to fight melanoma, neoplasm metastasis, lymphoma and non-hodgkin."

Answered by AI

Is Carboplatin a new medication being trialed?

"Currently, 489 phase 3 clinical trials are underway to investigate carboplatin's efficacy. These international studies 1676 active clinical trials and 86429 locations."

Answered by AI

How many individuals are included in this research project?

"From the information available on clinicaltrials.gov, it appears that this study is currently looking for 120 patients from 1 site. The trial was first announced on 11/17/2020 and has since been edited on 5/20/2021."

Answered by AI
~84 spots leftby Sep 2025